Expression of lncRNA MIAT in serum of patients with hepatocellular carcinoma and its clinical significance

Abstract

Abstract: Objective: To detect the expression of Long non-coding RNA (lncRNA) myocardial infraction association transcript (MIAT) in serum of patients with hepatocellular carcinoma (HCC) and to explore its clinical significance.Methods: The expression of MIAT in serum of HCC patients was detected by qRT-PCR assay. The value of MIAT expression in the diagnosis of HCC was assessed by ROC curve, and the relationship between MIAT expression with HCC disease progression and prognosis was analyzed.Results: MIAT was highly expressed in serum of HCC patients, and ROC curve showed that MIAT expression could be used as a serum marker for diagnosis of HCC. MIAT expression was closely related to tumor number, TNM stage and BCLC stage. MIAT expression decreased after resection of HCC and increased when HCC recurred.Conclusion: Serum MIAT level can be used as a biomarker for the diagnosis of HCC. It has potential clinical value in evaluating the malignant progression and surgical efficacy of HCC as well as predicting recurrence of HCC.

Key words: Long non-coding RNA, Myocardial infraction association transcript, Serum, Biomarkers

Yang Hang, Huang Yuhong, Wu Yunan. Expression of lncRNA MIAT in serum of patients with hepatocellular carcinoma and its clinical significance[J]. Electronic Journal of Liver Tumor, 2020, 7(2): 40-43.

References

[1] REN W, QI XS, JIA J, et al.Hepatocellular carcinoma[J]. Lancet, 2012, 380(9840):469.
[2] LU LC, CHENG AL, POON RTP.Recent advances in the prevention of hepatocellular carcinoma recurrence[J]. Semin Liver Dis, 2014, 34(4):427-434.
[3] Zucman-Rossi J, Villanueva A, Nault JC, et al.Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149(5): 1226-1239.
[4] SUN Y, MA L.New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis. Cancers (Basel), 2019, 11(2): E216.
[5] RAFIEE A, RIAZI-RAD F, HAVASKARY M, et al.Long noncoding RNAs: regulation, function and cancer[J]. Biotechnol Genet Eng Rev, 2018, 34(2):153-180.
[6] ZHENG C, HAO H, CHEN L, et al.Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis[J]. Clin Transl Oncol, 2017, 19(8): 961-968.
[7] LEE YR, KIM G, TAK WY, et al.Circulating exosomal noncoding RNAs as prognostic biomarkers in human hepatocellular carcinoma[J]. Int J Cancer, 2019, 144(6):1444-1452.
[8] XIANG Y, HUANG YG, SUN H, et al.Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation[J]. Biomed Pharmacother, 2019, 109:1630-1639.
[9] HUANG XL, GAO Y, QIN JJ, et al.lncRNA MIAT promotes proliferation and invasion of HCC cells via sponging miR-214[J]. Am J Physiol Gastrointest Liver Physiol, 2018, 314(5):G559-G565.
[10] OHNISHI Y, TANAKA T, YAMADA R, et al.Identification of 187 single nucleotide polymorphisms (SNPs) among 41 candidate genes for ischemic heart disease in the Japanese population[J]. Hum Genet, 2000, 106(3):288-292.
[11] ISHII N, OZAKI K, SATO H, et al.Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction[J]. J Hum Genet, 2006, 51(12):1087-1099.
[12] SUN C, HUANG LN, LI ZL, et al.Long non-coding RNA MIAT in development and disease: a new player in an old game[J]. J Biomed Sci, 2018, 25(1):23.
[13] WANG RJ, ZHAO LN, Ji LL et al. Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212[J]. Biomed Pharmacother, 2019, 118:109298.
[14] LIN D, XU HP, LIN JH, et al.Long non-coding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-1246[J]. Eur Rev Med Pharmacol Sci, 2019, 23(13):5795-5801.
[15] BOUNTALI A, TONGE DP, MOURTADA-MAARABOUNI M.RNA sequencing reveals a key role for the long non-coding RNA MIAT in regulating neuroblastoma and glioblastoma cell fate[J]. Int J Biol Macromol, 2019, 130:878-891.
[16] TAN J, LIU SZ, JIANG Q, et al.LncRNA-MIAT Increased in Patients with Coronary Atherosclerotic Heart Disease[J]. Cardiol Res Pract, 2019, 2019:6280194.
[17] XIANG Y, HUANG YG, SUN H, et al.Deregulation of miR-520d-3p promotes hepatocellular carcinoma development via lncRNA MIAT regulation and EPHA2 signaling activation[J]. Biomed Pharmacother, 2019, 109:1630-1639.